The gastrointestinal therapeutics market is projected to grow from USD 18.6 billion in 2026 to USD 32.1 billion by 2036, at a CAGR of 5.6%. Acid Suppressants (PPI or H2) will dominate with a 32.0% market share, while oral will lead the by route of administration segment with a 66.0% share.